Vanguard Personalized Indexing Management
NBIX icon

Vanguard Personalized Indexing Management’s Neurocrine Biosciences NBIX Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.85M Buy
11,004
+362
+3% +$53.7K 0.02% 678
2026
Q1 		$1.4M Sell
10,642
-596
-5% -$79.1K 0.01% 764
2025
Q4 		$1.59M Buy
11,238
+126
+1% +$18.3K 0.02% 689
2025
Q3 		$1.56M Buy
11,112
+77
+0.7% +$10.4K 0.02% 692
2025
Q2 		$1.39M Buy
11,035
+2,577
+30% +$296K 0.02% 710
2025
Q1 		$935K Sell
8,458
-2,622
-24% -$332K 0.01% 823
2024
Q4 		$1.51M Buy
11,080
+1,809
+20% +$224K 0.02% 576
2024
Q3 		$1.07M Buy
9,271
+207
+2% +$28.4K 0.02% 736
2024
Q2 		$1.23M Buy
9,064
+326
+4% +$44.7K 0.02% 587
2024
Q1 		$1.21M Sell
8,738
-2,117
-20% -$289K 0.03% 572
2023
Q4 		$1.43M Sell
10,855
-2,253
-17% -$259K 0.04% 470
2023
Q3 		$1.47M Buy
13,108
+786
+6% +$82.8K 0.04% 399
2023
Q2 		$1.16M Buy
12,322
+204
+2% +$19.9K 0.04% 495
2023
Q1 		$1.23M Buy
12,118
+453
+4% +$47.1K 0.04% 437
2022
Q4 		$1.39M Buy
11,665
+502
+4% +$58.8K 0.06% 385
2022
Q3 		$1.19M Sell
11,163
-140
-1% -$14.2K 0.05% 406
2022
Q2 		$1.1M Buy
11,303
+143
+1% +$13.2K 0.05% 416
2022
Q1 		$1.05M Buy
+11,160
New +$946K 0.05% 428
2021
Q4 		– Sell
-3,333
Closed -$320K – 1094
2021
Q3 		$320K Sell
3,333
-3,401
-51% -$321K 0.03% 738
2021
Q2 		$655K Buy
+6,734
New +$645K 0.07% 367

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Personalized Indexing Management's NBIX Position: Q2 2026 in Review

Vanguard Personalized Indexing Management increased its Neurocrine Biosciences (NBIX) stake by 3.4% in Q2 2026, buying an estimated $53.7K and bringing the position to 11,004 shares worth $1.85M. The position accounts for 0.02% of the portfolio, ranked #678.

Vanguard Personalized Indexing Management first reported a position in NBIX in Q2 2021 and has held it in 20 quarters since. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Vanguard Personalized Indexing Management held 11,004 shares of Neurocrine Biosciences worth $1.85M as of Q2 2026.
  • Vanguard Personalized Indexing Management bought 362 Neurocrine Biosciences shares in Q2 2026, an estimated $53.7K.
  • Neurocrine Biosciences made up 0.02% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #678 holding.
  • Vanguard Personalized Indexing Management first reported a position in Neurocrine Biosciences in Q2 2021 and has held it in 20 quarters since.
  • 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.